The relationship between lung inflammation and cardiovascular disease
S Van Eeden, J Leipsic, SF Paul Man… - American journal of …, 2012 - atsjournals.org
Acute and chronic lung inflammation is an underrecognized risk factor for cardiovascular
disease. Yet, there are compelling epidemiological data to indicate that airway exposures to …
disease. Yet, there are compelling epidemiological data to indicate that airway exposures to …
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure …
Aim To describe the baseline characteristics and treatment of the patients randomized in the
PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global …
PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global …
Generalizability of cardiovascular disease clinical prediction models: 158 independent external validations of 104 unique models
G Gulati, J Upshaw, BS Wessler, RJ Brazil… - … Quality and Outcomes, 2022 - Am Heart Assoc
Background: While clinical prediction models (CPMs) are used increasingly commonly to
guide patient care, the performance and clinical utility of these CPMs in new patient cohorts …
guide patient care, the performance and clinical utility of these CPMs in new patient cohorts …
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo …
Aims Hyperkalaemia in heart failure patients limits use of cardioprotective renin–angiotensin–
aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS‐9) is a selective …
aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS‐9) is a selective …
Guideline‐directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP‐HF registry
D Tomasoni, M Pagnesi, G Colombo… - European Journal of …, 2024 - Wiley Online Library
Aim Persistent symptoms despite guideline‐directed medical therapy (GDMT) and poor
tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced …
tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced …
Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр)(утверждены конференцией ОССН 15 декабря 2009 года)
ВЮ Мареев, ФТ Агеев, ГП Арутюнов… - Журнал сердечная …, 2010 - elibrary.ru
Введение В короткой преамбуле хочется предпослать этому доку менту несколько
определяющих позиций: Принятие в 2003 и 2006 годах съездами ВНок Нацио 1 …
определяющих позиций: Принятие в 2003 и 2006 годах съездами ВНок Нацио 1 …
Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disorders
JM Saavedra - Clinical science, 2012 - portlandpress.com
The effects of brain AngII (angiotensin II) depend on AT1 receptor (AngII type 1 receptor)
stimulation and include regulation of cerebrovascular flow, autonomic and hormonal …
stimulation and include regulation of cerebrovascular flow, autonomic and hormonal …
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study
AS Bhatt, AS Varshney, M Nekoui… - European Journal of …, 2021 - Wiley Online Library
Aims Implementation of guideline‐directed medical therapy (GDMT) for heart failure with
reduced ejection fraction (HFrEF) remains incomplete. Non‐cardiovascular hospitalization …
reduced ejection fraction (HFrEF) remains incomplete. Non‐cardiovascular hospitalization …
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced) …
Background It is important to evaluate whether a new treatment for heart failure with reduced
ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As …
ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As …
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
B Pitt, GL Bakris, DA Bushinsky, D Garza… - European journal of …, 2015 - Wiley Online Library
Aims We evaluated the effects of patiromer, a potassium (K+)‐binding polymer, in a pre‐
specified analysis of hyperkalaemic patients with heart failure (HF) in the OPAL‐HK trial …
specified analysis of hyperkalaemic patients with heart failure (HF) in the OPAL‐HK trial …